Infectious Disease and Tropical Medicine
2025 DATA
Leaders
Research
|
LocationDivision of Infectious Diseases Fundación Jiménez Díaz University Hospital. Avda. Reyes Católicos, 2 - 28040 Madrid (Spain). HIV and Viral Hepatitis Research Laboratory Rey Juan Carlos University Hospital. C/ Gladiolo s/n - 28933 Móstoles (Spain). KeywordsHIV; Viral Hepatitis; Cellular Immune Response; HIV and Cancer; Inflammation; HIV vaccines; Viral persistence and latency; Sexually Transmitted Infections (STIs); Tropical Diseases; Cardiovascular Infections. |
Gender perspective

Summary of activity
The group’s main research lines comprise both basic and clinical studies on HIV infection, with a particular focus on investigating the mechanisms underlying viral persistence and latency, the factors associated with viral control, the role of chronic inflammation, and the interactions between HIV infection and cancer. The group is also actively involved in the evaluation of novel antiretroviral therapies and HIV vaccine candidates. In addition, the Group conducts clinical research in other areas of infectious diseases and tropical medicine, contributing to the advancement of knowledge, diagnosis and treatment of a broad range of infectious conditions.
Contributions to society
The scientific knowledge generated by our group represents a significant contribution to addressing the challenges faced by vulnerable populations affected by HIV infection, other infectious diseases and cancer. Through rigorous research, collaboration with patient associations, and the promotion of preventive education initiatives, we actively contribute to improving public health outcomes and reducing health inequalities from a social justice perspective. Our work supports the development of innovative strategies for the prevention, diagnosis and treatment of infectious diseases, while also enhancing the quality of life of affected individuals. By fostering knowledge transfer and engagement with healthcare professionals, patients and the wider community, the group seeks to maximise the societal impact of its research and contribute to evidence-based healthcare policies and practices.
Collaborations
The group actively collaborates with both intramural research teams across all institutions comprising IIS-FJD and with external groups at the national and international levels. Notable collaborations include the Centre for Virus Research at the Westmead Institute for Medical Research, Faculty of Medicine and Health, The University of Sydney (Australia); the Faculty of Medicine of the Pedagogical and Technological University of Colombia (UPTC); the Proteomics Unit of the Ramón y Cajal Institute for Health Research (IRYCIS) at Ramón y Cajal University Hospital; the Immunogenetics Unit of the Department of Experimental Biology at the University of Jaén; the Maimónides Health Research Institute of Córdoba (IMIBIC) and Córdoba Science and Technology Park; the National Centre for Microbiology (ISCIII) in Majadahonda, Madrid; the Proteomics Unit of the Spanish National Centre for Cardiovascular Research (CNIC) in Madrid; the Departments of Internal Medicine at Gregorio Marañón University Hospital and Clínico San Carlos University Hospital, both in Madrid; the Alberto Sols Biomedical Research Institute (CSIC-UAM); the Tumour Immunomodulation Group at the Research Institute of 12 de Octubre University Hospital; the Spanish National Cancer Research Centre (CNIO) in Madrid;Vall d’Hebron University Hospital in Barcelona; the National Centre for Electron Microscopy (ICTS) at the Complutense University of Madrid; the Madrid Science Park Foundation (UAM); the Metabolomics and Bioanalysis Centre of CEU San Pablo University in Madrid; and the Bioinformatics Unit of CNIC.
PhD Theses

List of publications
Antiretroviral treatment in people living with HIV with late diagnosis initiating ART with DTG/3TC or BIC/TAF/FTC: A real-world cohort analysis.
Schuettfort G, Borch J, Cabello A, Crusells M, Górgolas M, Herrmann E, Hidalgo-Tenorio C, Lopez J, Mican R, Navarro-Soler R, Negredo E, Noe S, Puig J, Pulido F, Serrao R, Rockstroh J, Rodriguez S, Stephan C, Torralba M, Trigo D, Vehreschild M, Haberl AE.
HIV Med. 2026 Jan.27(1):96-105.
PMID: 41054831
FI: 3,2
http://dx.doi.org/10.1111/hiv.70119
Total neoadjuvant therapy in rectal cancer: The FOREST protocol, a patient-centered approach that clusters two cohorts with different outcomes.
Guadalajara H, Domínguez-Tristancho JL, Mateo RF, Leon-Arellano M, Sanz-Baro R, Geraldi E, Hormigo-Sanchez AI, Megías VMC, Cobos MP, Miras PM, Zulueta BL, Garcia-Arranz M, Foncillas JG, Caramés C, García-Olmo D.
Int J Cancer. 2026 Feb 01.158(3):697-706.
PMID: 40947902
FI: 4,7
http://dx.doi.org/10.1002/ijc.70126
MAPT p.V363I mutation in a patient with presenile dementia and late amyotrophic lateral sclerosis.
Gómez-Tortosa E, Agüero-Rabes P, Roa-Escobar J, Sainz MJ, Viñas J, Téllez R, Martínez-Ulloa P, Pérez-Pérez J.
Amyotroph Lateral Scler Frontotemporal Degener. 2025 Dec 27:1-4.
PMID: 41454905
FI: 2,8
http://dx.doi.org/10.1080/21678421.2025.2604238
Assessing the quality of life in patients with complex chronic conditions: Cronimad study.
Cubo Romano P, García de la Torre P, Gracia Lorenzo V, González Ferrer R, Madroñal Cerezo E, Bellver Álvarez TM, Moya Mateo EM, Andrés Del Olmo B, Castañeda Pastor A, Casas Rojo JM, Members of CRONIMAD Group.
BMC Geriatr. 2025 Dec 08.
PMID: 41361774
FI: 3,8
http://dx.doi.org/10.1186/s12877-025-06359-w
Epidemiology and Risk Factors for HCV Infection Among MSM With or at Risk of HIV in Madrid (2022-2024).
Ryan P, Berenguer J, Ramos-Ruperto L, Vera M, Martín-Carbonero L, Pérez-Latorre L, De Los Santos I, Pinto A, Vivancos MJ, Orviz E, Álvarez B, Sanz J, Ruiz-Seco P, Torres R, Brazal B, De Miguel M, López-Centeno B, Jarrín I, Resino S, Bellón JM, González-García J.
Open Forum Infect Dis. 2025 Dec.12(12):ofaf678.
PMID: 41311917
FI: 3,8
http://dx.doi.org/10.1093/ofid/ofaf678
Practical management of heart failure in hospital at home: recommendations from the Spanish Society of Internal Medicine and the Spanish Society of Hospital at Home.
Ruiz-Castellano M, Aguiar D, Aguilar-Rodríguez F, Cubo P, Flox G, Murcia JM, Coloma E, Gracia VM, Vicente C, Salamanca-Bautista P.
Rev Clin Esp (Barc). 2025 Dec.225(10):502399.
PMID: 41232715
FI: 1,7
http://dx.doi.org/10.1016/j.rceng.2025.502399
Functional cure of HIV-1 infection in an exceptional elite controller: a case report.
Benito JM, Lopez-Bernaldo JC, Fisher K, Pereyra-Casanova A, Cabello A, Estrada V, Gorgolas M, Buzon MJ, Palmer S, Rallón N.
Lancet HIV. 2025 Dec.12(12):e850-e860.
PMID: 41202829
FI: 13
http://dx.doi.org/10.1016/S2352-3018(25)00233-4
A prospective assessment of the efficacy and durability of long-acting cabotegravir and rilpivirine in individuals with HIV in Spain (RELATIVITY study).
Buzón-Martín L, Montes ML, Pedrero R, Galindo MJ, Santacreu-Guerrero M, Alemán MR, Torralba M, Díaz de Santiago A, Fanjul F, Rodríguez A, Cabello A, Crusells MJ, Navarro MDC, Aguilera M, Hidalgo-Tenorio C, Morano-Amado LE, Vinuesa D, De Andres C, Bernal-Morell E, Martínez-Álvarez RM, Cabello-Clotet N, Tiraboschi J, Montero MDC, Vivancos-Gallego MJ, Díez C, Calderón R, De Zárraga MA, Gisbert L, Romero-Palacios A, Cabo R, Soler JF, Sepúlveda MA, Sánchez-Guirao AJ, Escrich C, Arnaiz De Las Revillas F, Ferreira E, Valentín B, Lérida A, Llenas-García J, Gómez A, Losa JE, Alonso B, Sanz J, Masiá M, Pernas H, Corte JJ, Garcinuño MÁ, Gainzarain JC, Estébanez M, García-Navarro MDM, Barragán P, Ramos N, Clavero M, Millán M, Del Álamo M, Egido M, De La Calle B, Ferrero OL, Troya J.
J Antimicrob Chemother. 2025 Dec 02.80(12):3438-3451.
PMID: 41128149
FI: 3,6
http://dx.doi.org/10.1093/jac/dkaf389
Morphofunctional parameters as predictors of autologous hematopoietic stem cell transplantation outcomes.
Cornago J, Dassen C, Calderón C, Mahíllo I, Pardo L, López-Lorenzo JL, Hormigo AI, Caballero JC, Domingo-González A, Capellán R, Iturrate I, de Camino BP, Sánchez-Fernández MS, Teixeira Á, Del Pecho M, Llamas P, Solán L.
Front Nutr. 2025.12:1666754.
PMID: 41080170
FI: 5,1
http://dx.doi.org/10.3389/fnut.2025.1666754
Nutritional support in pediatric patients with extracorporeal membrane oxygenation: new insights.
Gómez-Becerra KI, Robledo-Valdez M, Morante-Ruiz M, Soto-Holguín MCM, Cervantes-Guevara G, Ramírez-Ochoa S, Cervantes-Pérez G, Cervantes-Pérez LA, Vicente-Hernández B, Castro-Campos KD, Flores-Alatorre MG, Cervantes-Pérez E.
Arch Cardiol Mex. 2025.95(3):215-223.
PMID: 40763815
FI: 0,7
http://dx.doi.org/10.24875/ACM.24000135
Aging with HIV: a cross-sectional look at comorbidities.
Montes MC, Rueda-Camino JA, Rallón N, Nistal-Juncos S, Barba Martín R.
Rev Clin Esp (Barc). 2025.225(6):502310.
PMID: 40348277
FI: 1,7
http://dx.doi.org/10.1016/j.rceng.2025.502310
The Chagas non-endemic (ChaNoE) cohort: Aims and study protocol.
Bosch-Nicolau P, Herrero-Martínez JM, Arsuaga M, Chamorro-Tojeiro S, Carrillo I, Bea-Serrano C, Llenas-García J, Pérez-Recio S, Fernández-Pedregal E, Crespillo-Andújar C, Silgado A, Pérez-Ayala A, de la Calle-Prieto F, Prieto-Pérez L, Pérez-Molina JA, Molina I.
PLoS One. 2025.20(4):e0320637.
PMID: 40233055
FI: 2,6
http://dx.doi.org/10.1371/journal.pone.0320637
Nocardia arthritidis Infection in an Immunocompetent Patient.
Morante-Ruiz M, Arroyo-Fernández R, Petkova-Saiz E.
Open Respir Arch. 2025.7(1):100397.
PMID: 40028442
FI: 0
http://dx.doi.org/10.1016/j.opresp.2025.100397
Ultrasound-guided postmortem biopsies in the ICU: diagnostic yield and future applications beyond the pandemic.
Vidal González Á, Páez Vargas JJ, Robaglia D, Vicente Montaña AM, Fortes Alen JR, Prieto Pérez L.
Med Intensiva (Engl Ed). 2025 Nov 26:502362.
PMID: 41309369
FI: 3,1
http://dx.doi.org/10.1016/j.medine.2025.502362
Diagnosis of HIV infection during pregnancy: Trends from a national cohort in Spain.
Suárez-García I, Alejos B, Moreno C, Izquierdo R, de la Cámara SP, Resa-Infante P, Merino VS, García-Arriaza J, Cabello-Úbeda A, Pérez-Martínez L, Palacios R, Hernando V, Jarrín I, CoRIS cohort.
HIV Med. 2025 Nov 21.
PMID: 41267621
FI: 3,2
http://dx.doi.org/10.1111/hiv.70148
Postmortem ultrastructural lung and liver injury in a critically ill COVID-19 patient.
González ÁV, Montaña AM, Piris MC, Prieto-Pérez L.
BMJ Case Rep. 2025 Nov 12.18(11).
PMID: 41224683
FI: 0,5
http://dx.doi.org/10.1136/bcr-2025-267289
Counterreply to the letter ""About the study of geriatric syndromes: the definition matters"".
Montes MC, Rueda-Camino JA, Rallón N, Nistal-Juncos S, Barba-Martín R.
Rev Clin Esp (Barc). 2025 Nov.225(9):502385.
PMID: 41167423
FI: 1,7
http://dx.doi.org/10.1016/j.rceng.2025.502385
Trends in pulmonary embolism incidence in Spain (2016-2022): an analysis of differences among autonomous communities.
Gimena-Rodríguez FJ, Barba-Martín R, Angelina-García M, Trujillo-Luque D, Joya-Seijo MD, Rueda-Camino JA.
Rev Clin Esp (Barc). 2025 Nov.225(9):502377.
PMID: 41138975
FI: 1,7
http://dx.doi.org/10.1016/j.rceng.2025.502377
Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort.
Buzón L, Bernardino JI, Galindo Puerto MJ, Martín-Torres J, Alemán Valls MR, Torralba González de Suso M, Díaz de Santiago A, Fanjul F, Rodríguez A, Cabello Úbeda A, Pedrero-Tomé R, Crusells Canales MJ, Calzado Isbert S, Aguilera García M, Hidalgo Tenorio C, Morano L, Vinuesa García D, de Andrés David C, Bernal Morell E, Martínez Álvarez RM, Cabello Clotet N, Tiraboschi J, Gimeno García A, Vivancos MJ, Troya J, RELATIVITY Cohort Group∗, RELATIVITY Cohort Group∗.
AIDS. 2025 Oct 23.
PMID: 41183264
FI: 3,1
http://dx.doi.org/10.1097/QAD.0000000000004388
When Fungal Prophylaxis Fails: A Rare Case of Rhodotorula mucilaginosa Fungemia with Suspected Abdominal Origin.
Asensi-Díaz E, Barbero Del Olmo L, Urrutia P, Lario A, Gómez-G de la Pedrosa E, García-Ruiz de Morales AG, Martín-Dávila P, Fortún J.
J Fungi (Basel). 2025 Oct 08.11(10).
PMID: 41149913
FI: 4
http://dx.doi.org/10.3390/jof11100723
Sudden onset of acute abdominal pain.
Polo J, López-Botet B, Del Pozo AI.
Emerg Med J. 2025 Oct 20.42(11):727-735.
PMID: 41115697
FI: 2,8
http://dx.doi.org/10.1136/emermed-2025-214944
The Rising Impact of HPV Infection in the Antiretroviral Therapy (ART) Era.
Asensi-Díaz E, Carrillo I, Al-Hayani A, Mejías-Ledesma M, Guadalajara H, Azinovic I, Trsitancho JLD, Vidal LS, Castellano V, García-Olmo D, Górgolas M, Cabello-Úbeda A.
Curr HIV Res. 2025 Oct 14.
PMID: 41102961
FI: 1
http://dx.doi.org/10.2174/011570162X381694250925045507
Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults with HIV (INSTINCT/GESIDA10918 Study).
Serrano-Villar S, Martín-Pedraza L, Tiraboschi J, Novella M, Cabello-Úbeda A, López-Cortés L, Busca C, Torralba M, Crusells MJ, Hidalgo-Tenorio C, Estrada V, Del Amo-de Palacios A, Díaz de Santiago A, Fons-Contreras M, Santos J, Bernal E, Montero-Alonso M, Troya J, Blanco JR, Burgos J, de Miguel M, Moreno S.
Clin Infect Dis. 2025 Oct 10.
PMID: 41070447
FI: 7,3
http://dx.doi.org/10.1093/cid/ciaf565
Long-acting cabotegravir and rilpivirine for the treatment of people with HIV: current landscape and challenges ahead.
Buzón-Martín L, Cabello A, Díaz de Santiago A, Galindo MJ, Hidalgo-Tenorio C, Romero-Palacios A, Troya J.
J Antimicrob Chemother. 2025 Oct 03.80(10):2565-2586.
PMID: 40794804
FI: 3,6
http://dx.doi.org/10.1093/jac/dkaf246
Dolutegravir (DTG) + Lamivudine (3 TC) in Antiretroviral-Naive Adults With HIV With and Without Genotypic Resistance Testing Results: 96-Week Effectiveness and Tolerability of REDOLA Study.
Cabello-Ubeda A, López Bernardo de Quirós JC, Mena Á, Torralba M, Martín Carbonero L, Gutiérrez Á, Vergas J, Pinto A, Tejerina F, Palmier E, Sanz J, Górgolas M, Pulido F.
J Acquir Immune Defic Syndr. 2025 Oct 01.100(2):e4-e7.
PMID: 40673705
FI: 2,2
http://dx.doi.org/10.1097/QAI.0000000000003721
A Phase IV, open-label, single-arm, multicentric clinical trial for evaluation of Human Papillomavirus 9vHPV vaccine immunogenicity in Men Who Have Sex with Men living with HIV: GeSIDA Study 10017.
Ron R, Díaz-García C, Sendagorta E, Cabello-Úbeda A, Moreno E, Crespillo-Andújar C, Feltes-Ochoa R, Carrillo-Acosta I, Navarro-Soler R, Esteban H, Górgolas M, Moreno S, Pérez-Molina JA, Serrano-Villar S.
Clin Infect Dis. 2025 Aug 06.
PMID: 40794702
FI: 7,3
http://dx.doi.org/10.1093/cid/ciaf435
Sex-based differences in access to reperfusion therapies for pulmonary embolism in Spain during the 2016-2022 period.
Rueda-Camino JA, Angelina-García M, Trujillo-Luque D, Joya-Seijo MD, Teigell-Prieto L, Novalbos-Partida JÁ, Gimena-Rodríguez FJ, Barba-Martín R.
Thromb Res. 2025 Aug.252:109371.
PMID: 40479910
FI: 3,4
http://dx.doi.org/10.1016/j.thromres.2025.109371
Real-world evidence of dalbavancin effectiveness as consolidation therapy in infective endocarditis due to Enterococcus spp.
Hidalgo-Tenorio C, Sadyrbaeva-Dolgova S, Aparicio-Minguijón E, Alarcón A, Plata A, Martínez Marcos FJ, Álvarez-Álvarez B, Loeches B, Varisco B, Estévez A, Herrero C, Escrihuela-Vidal F, Boix-Palop L, Ruch Y, Valour F, Issa N, Thill P, Nguyen S, Poloni S, Millot R, Peiffer-Smadja N, Boyer-Chammard T, Diallo K, Larcher R, Miró JM, Luque-Paz D.
J Microbiol Immunol Infect. 2025 Aug.58(4):429-436.
PMID: 40155302
FI: 3,7
http://dx.doi.org/10.1016/j.jmii.2025.03.001
Targeted Antibiotic Prophylaxis in Percutaneous Nephrolithotomy: Results of a Protocol Based on Preoperative Urine Culture and Risk Assessment.
Osorio-Ospina F, Bueno-Serrano G, Alcoba-García MP, Tabares-Jiménez J, Gómez-Jordana-Mañas B, García-Criado E, Ruiz-de-Castroviejo J, Pérez-Aizpurua X, Tufet-I-Jaumot JJ, González-Páez R, Matta-Pérez JC, Yanes-Glaentzlin B, Jiménez-Abad JF, Alcázar Peral JM, Carrasco Antón N, Petkova-Saiz E, González-Enguita C.
J Clin Med. 2025 Jul 24.14(15).
PMID: 40806870
FI: 2,9
http://dx.doi.org/10.3390/jcm14155249
High Prevalence of Multidrug-Resistant Bacterial Colonization Among Patients and Healthcare Workers in a Rural Ethiopian Hospital.
Hidalgo E, Alvaredo-Carrillo T, Gil-Belda JM, Portela-Pino C, Bares-Moreno C, Jareño-Moreno S, de la Fuente P, Platero L, Pérez-Tanoira R.
Antibiotics (Basel). 2025 Jul 17.14(7).
PMID: 40724018
FI: 4,6
http://dx.doi.org/10.3390/antibiotics14070717
Trends in HCV Infection Prevalence Among People with HIV in Spain Over Two Decades (2002-2023).
Berenguer J, Fanciulli C, Arcos MM, Vivancos MJ, Domingo P, Hernando A, Barrado J, Ryan P, Navarro J, Palacios R, Morano LE, Iribarren JA, Martínez R, Galindo MJ, de Los Santos I, López-Cruz I, Rivero A, Pérez-Latorre L, Giner L, Fariñas MC, García C, Montero-Alonso M, Ferrero ÓL, Villoslada A, Soler-González JF, Sanz J, Rodríguez S, Losa JE, Bernal E, Veloso S, Pérez-Martínez L, Mateos F, Arbonés L, Franch R, Corps D, Martín C, Alonso G, Clavero-Olmos M, Silvariño R, Teira R, Belinchón O, de Miguel M, Jarrín I, González-García J.
Clin Infect Dis. 2025 Jul 24.
PMID: 40708503
FI: 7,3
http://dx.doi.org/10.1093/cid/ciaf407
Plasma calprotectin as a severity biomarker in pediatric invasive Streptococcus pyogenes infections: insights from a multicenter immune profiling study during an outbreak.
Avendaño-Ortiz J, Aguilera-Alonso D, Rodríguez CM, Oteo-Iglesias J, Lozano-Rodríguez R, López-Collazo E, López-Suárez A, Rello-Saltor V, Jimenez AB, Jiménez B, Del Campo R, Cantón R, Calvo C, Saavedra-Lozano J.
J Microbiol Immunol Infect. 2025 Jul 15.
PMID: 40695673
FI: 3,7
http://dx.doi.org/10.1016/j.jmii.2025.07.008
Acute infectious gastroenteritis in childhood: the role of rapid multiplex molecular syndromic panels in diagnosis and clinical management.
Jiménez-Jiménez AB, Galán-Sánchez F, Hortelano MG, Fumadó V, Salar-Vidal L, Ramos-Amador JT, Menasalvas-Ruiz AI.
Rev Esp Quimioter. 2025 Jul 03.38(4):258-277.
PMID: 40607535
FI: 2,2
http://dx.doi.org/10.37201/req/026.2025
Drug Addiction in Gay and Bisexual Men Living with HIV Engaged in Sexualized Drug Use: Recent Drug Use, Polydrug and Depressive Symptoms as Predictors.
Ollero MJF, Ryan P, Dolengevich-Segal H, Cano-Smith J, Ramos-Ruperto L, Cabello A, Sanchez-Conde M, Cabello N, Sanz J, García-Fraile LJ, Perez-Latorre L, Bisbal O, De La Fuente S, Losa JE, González-Baeza A.
AIDS Behav. 2025 Jul.29(7):2324-2335.
PMID: 40185963
FI: 2,4
http://dx.doi.org/10.1007/s10461-025-04695-x
Rapid start with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as initial treatment in people with human immunodeficiency virus-1 (HIV-1): A systematic literature review of clinical and patient-reported outcomes.
Ghosn J, Chow J, Gandhi M, Górgolas M, Al-Hayani A, Tookes H, Lee M, Kaiser EF, Malebranche D, Bognar FA, Gandhi-Patel B, Dai L.
HIV Med. 2025 Jun 26.
PMID: 40566994
FI: 3,2
http://dx.doi.org/10.1111/hiv.70065
Evolution of antibiotic resistance pattern of Helicobacter pylori in Spanish children: A 10-year multicenter study.
Botija G, Barrio J, Martínez-Escribano B, Gallardo M, Urruzuno P, Alonso N, Vázquez JA, Barrio A, Recio A, Miranda-Cid C, Rizo J, González-Abad MJ, Pérez-Fernández E, Cilleruelo ML.
J Pediatr Gastroenterol Nutr. 2025 Jun 19.
PMID: 40537963
FI: 2,7
http://dx.doi.org/10.1002/jpn3.70123
Daily Steps After Hip Fracture in Older Adults and Their Relationship with Functional Recovery.
Bermejo Boixareu C, Pecharroman Anton L, Mateos Del Amo L, Benito Fuentes M, Piña Delgado G, de Ussía MDB, Royuela Vicente A, Martín-Sánchez FJ, Martínez Ruiz RM, Fagundez García C, Bielza Galindo R, García Cárdenas V, Valverde Fontcuberta C, de Villaumbrosía CG, Sanz-Pérez MI, Campo Loarte J.
J Clin Med. 2025 Jun 02.14(11).
PMID: 40507668
FI: 2,9
http://dx.doi.org/10.3390/jcm14113906
Recommendations for the prevention of fragility fractures: a consensus from international experts and Ibero-American scientific societies.
Sáez-López P, Aldecoa Álvarez-Santullano C, Arboiro-Pinel R, Baquero Úbeda JL, Bastida Calvo JC, Baixaulí García F, Cassinello Ogea C, Condorhuamán Alvarado PY, Cortés Berdonces M, Cuadra Llopart L, Fernández Martínez N, Giner García M, Micó Pérez RM, Mur Molina B, Naranjo Hernández A, Neyro Bilbao JL, Ojeda-Thies C, Palacios Gil Antuñano S, Santiñá Vila M, Soto Bonel J, Tarazona-Santabalbina FJ.
Arch Osteoporos. 2025 Jun 12.20(1):76.
PMID: 40504279
FI: 2,8
http://dx.doi.org/10.1007/s11657-025-01551-2
Characterization of new HIV diagnoses made in hospital emergency departments through the ""Leave Your Mark"" program.
Calpe Delgado P, Muñoz P, Pizarro Portillo A, Álvarez Rodríguez V, Díaz Salado ÁI, Arenas Berenguer I, Álvarez Alonso M, Gargallo García E, Fernández Salgado F, Real Martín AE, Cabrera Rodrigo I, Carrasquel Regalade A, Moreno Planelles MÁ, Jurado Otero M, Sanz Lorente R, Pérez Ordoño L, Carrero Fernández A, González Del Castillo J, representing the Madrid HIV network.
Enferm Infecc Microbiol Clin (Engl Ed). 2025 Jun 02.
PMID: 40461405
FI: 2,5
http://dx.doi.org/10.1016/j.eimce.2025.05.006
Artesunate-induced anaemia: A case report of a pharmacological complication to consider.
Asensi-Díaz E, Morante-Ruiz M, Asensio-Mathews P, de Górgolas Hernández-Mora M.
Parasitol Int. 2025 Jun.106:103029.
PMID: 39793851
FI: 1,9
http://dx.doi.org/10.1016/j.parint.2025.103029
Long-Term Elite Controllers of HIV-1 Infection Exhibit a Deep Perturbation of Monocyte Homeostasis.
Benito JM, Jiménez-Carretero D, Valentín-Quiroga J, Mahillo I, Ligos JM, Restrepo C, Cabello A, López-Collazo E, Sánchez-Cabo F, Górgolas M, Rallón N.
Int J Mol Sci. 2025 Apr 22.26(9).
PMID: 40362169
FI: 4,9
http://dx.doi.org/10.3390/ijms26093926
Body mass index and prognosis of infective endocarditis.
Frías-García R, Muñoz García P, Machado Vilchez M, Cuerpo Caballero G, Rodríguez-García R, Rodríguez-Esteban MÁ, Fariñas-Álvarez MC, Miró Meda JM, Gutiérrez Villanueva A, Ojeda-Burgos G, Goikoetxea-Agirre AJ, Bernal Palacios M, Martínez-Sellés M, Spanish Collaboration on Endocarditis-Grupo de Apoyo al Manejo de la Endocarditis Infecciosa en España (GAMES), Spanish Collaboration on Endocarditis-Grupo de Apoyo al Manejo de la Endocarditis Infecciosaen España (GAMES).
Infect Dis (Lond). 2025 Apr 01:1-8.
PMID: 40169014
FI: 2,3
http://dx.doi.org/10.1080/23744235.2025.2481914
Predictive factors of gait recovery after hip fracture: a scoping review.
González de Villaumbrosia C, Barba R, Ojeda-Thies C, Grifol-Clar E, Álvarez-Diaz N, Álvarez-Espejo T, Cancio-Trujillo JM, Mora-Fernández J, Pareja-Sierra T, Barrera-Crispín R, Calle-Egusquiza A, Capdevila-Reniu A, Carrasco-Paniagua C, Cervera Díaz MC, Condorhuamán-Alvarado P, Cotano-Abad L, Cuadra-Llopart L, García-Cárdenas V, González-Chávez S, Hernández-Sánchez LA, Herrero-Pinilla B, López-Castro J, Montero-Fernández N, Muñoz-Pascual A, Muñoz-Vélez M, Ortés-Gómez R, Sáenz-Tejada A, Sanz-Reig J, Torras-Cortada S, Ramos Cortés M, Sáez-López P.
Age Ageing. 2025 Mar 03.54(3).
PMID: 40100147
FI: 7,1
http://dx.doi.org/10.1093/ageing/afaf057
Complicated malaria caused by Plasmodium falciparum with parasitemia >50.
Morante-Ruiz M, Ortega-Portas C, Betancourt-Cuadra LJ, Górgolas Hernández-Mora M.
Enferm Infecc Microbiol Clin (Engl Ed). 2025 Mar.43(3):175-176.
PMID: 40037748
FI: 2,5
http://dx.doi.org/10.1016/j.eimce.2024.07.010
Profile and Usefulness of Serum Cytokines to Predict Prognosis in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
Villacieros-Álvarez J, Espejo C, Arrambide G, Dinoto A, Mulero P, Rubio-Flores L, Nieto P, Alcalá C, Meca-Lallana JE, Millan-Pascual J, Martínez-García P, Bernard-Valnet R, González-Suárez I, Orviz A, Téllez R, Navarro Cantó L, Presas-Rodríguez S, Martínez-Yélamos S, Cuello JP, Alonso A, Piñar Morales R, Álvarez Bravo G, Benyahya L, Trouillet-Assant S, Dyon-Tafan V, Froment Tilikete C, Ruet A, Bourre B, Deschamps R, Papeix C, Maillart E, Kerschen P, Ayrignac X, Rovira À, Auger C, Audoin B, Montalban X, Tintore M, Mariotto S, Cobo-Calvo A, Marignier R.
Neurol Neuroimmunol Neuroinflamm. 2025 Mar.12(2):e200362.
PMID: 39752619
FI: 8,4
http://dx.doi.org/10.1212/NXI.0000000000200362
Impact of training healthcare professionals in the detection and management of neuropsychiatric comorbidities in people with HIV: The CONECTAR project in Spain.
Blanch J, Martinez E, Mena Á, Dueñas C, Bernal E, Cabello A, Hayek M, Mican R, Morillo-Verdugo R, Sainz M, Conde CG, Perez-Valero I.
HIV Med. 2025 Feb 24.
PMID: 39995253
FI: 3,2
http://dx.doi.org/10.1111/hiv.70002
Plasma Biomarkers in the Distinction of Alzheimer's Disease and Frontotemporal Dementia.
Gómez-Tortosa E, Agüero-Rabes P, Ruiz-González A, Wagner-Reguero S, Téllez R, Mahillo I, Ruiz-Calvo A, Sainz MJ, Nystrom AL, Del Ser T, Sánchez-Juan P.
Int J Mol Sci. 2025 Jan 30.26(3).
PMID: 39940998
FI: 4,9
http://dx.doi.org/10.3390/ijms26031231
Efficacy of sulfasalazine on recurrent acute anterior uveitis: a three-year follow-up.
Avello-Gorostidi A, Hernanz I, Robles-Barrena I, Olivas-Vergara O, Borges PE, Arconada-López C, Romero-Bueno F, Sánchez-Pernaute O, Carreño E.
Int Ophthalmol. 2025 Jan 24.45(1):36.
PMID: 39853487
FI: 1,4
Projects, contracts and observational studies
PUBLIC
Sources of public funding for projects being developed at the IIS-FJD:

|
REFERENCE |
PROJECT TITLE |
PRINCIPAL RESEARCHER |
TYPE OF PROJECT |
TOTAL FUNDING |
|
ICI24/00059 |
A RANDOMISED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED CLINICAL TRIAL OF COLCHICINE TO REDUCE CORONARYARTERY INFLAMMATION IN PEOPLE WITH HIV. COLCOHIV |
CABELLO UBEDA, ALFONSO |
CLINICAL RESEARCH PROJECTS. ISCIII |
€27,830.00 |
|
PI24/00335 |
INTERACCIONES ENTRE CÁNCER E INFECCIÓN POR VIH: IMPACTO EN LA RESPUESTA INMUNOLÓGICA Y EN LA CARGA DE COMORBILIDADES |
RALLON AFANADOR, NORMA IBON |
CLINICAL RESEARCH PROJECTS. ISCIII |
€227,500.00 € |
PRIVATE
|
REFERENCE |
PROJECT TITLE |
PRINCIPAL RESEARCHER |
TYPE OF PROJECT |
|
GLD22-17648 |
ESTRATIFICACIÓN Y ABORDAJE DEL ESTIGMA EN PVIH |
CABELLO UBEDA, ALFONSO |
RESEARCH PROJECTS. COMPETITIVE |
|
GLD22_00197 |
EXOSOMAS COMO DESENCADENANTES DEL DESARROLLO DE CÁNCER NO DEFINITORIOS DE SIDA EN EL CONTEXTO DE LA PATOGÉNESIS DEL VIH |
RALLON AFANADOR, NORMA IBON |
RESEARCH PROJECTS. COMPETITIVE |
|
2024.104 |
AYUDA PARA PUBLICACIÓN CIENTÍFICA MAIC CONTINUUM |
ALBIÑANA PEREZ, ALBERTO |
RESEARCH PROJECTS |
|
30681/010 |
AYUDA PARA LA CONTRATACIÓN DE PERSONAL DE INVESTIGACIÓN EN ENFERMEDADES INFECCIOSAS Y MEDICINA TROPICAL |
GORGOLAS HERNANDEZ-MORA, MIGUEL |
PERSONNEL / HUMAN RESOURCES |
|
4298/011 |
PROGRAMA DE BECAS DE INVESTIGACIÓN CIENTÍFICA |
GORGOLAS HERNANDEZ-MORA, MIGUEL |
PERSONNEL / HUMAN RESOURCES |
|
4131/001 |
DISPOSICIÓN DE UN DIETISTA EN LA UNIDAD DE GERIATRÍA DEL HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ |
HORMIGO SANCHEZ, ANA ISABEL |
PERSONNEL / HUMAN RESOURCES |
Clinical trials
The clinical trials listed below were in the recruitment phase in 2025. If you are interested in participating in any of the currently open trials, more information is available on the website (https://ensayos.quironsalud.es/)
|
EudraCT Number |
TITLE |
PHASE |
MC1 |
INT2 |
PRINCIPAL RESEARCHER |
|
2022-500883-37-00 |
ESTUDIO FASE 1/2, MULTINACIONAL, OBSERVADOR CIEGO, ALEATORIZADO Y CONTROLADO CON PLACEBO PARA EVALUAR LA SEGURIDAD Y EFICACIA DE LA VACUNA EN INVESTIGACIÓN DE GSK FRENTE A NEISSERIA GONORRHOEAE GMMA (NGG) CUANDO SE ADMINISTRA A ADULTOS SANOS DE ENTRE 18 Y 50 AÑOS DE EDAD |
I/II |
YES |
YES |
MIGUEL GORGOLAS HERNANDEZ-MORA |
|
2024-519319-32-00 |
A SEAMLESS PHASE 1/2, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO ASSESS THE SAFETY AND IMMUNOGENICITY OF A UTI VACCINE WHEN ADMINISTERED TO ADULTS 18 THROUGH 64 YEARS OF AGE AND CLINICAL EFFICACY WHEN ADMINISTERED TO FEMALES 18 THROUGH 64 YEARS OF AGE |
I/II |
YES |
YES |
MIGUEL GORGOLAS HERNANDEZ-MORA |
|
2025-520629-19-00 |
ESTUDIO EXPLORATORIO FASE 1B, MULTICÉNTRICO, ALEATORIZADO Y ABIERTO PARA INVESTIGAR EL IMPACTO DE LA ADMINISTRACIÓN DE VH3810109 INTRAVENOSO CON O SIN FOSTEMSAVIR ORAL EN COMBINACIÓN CON TERAPIA ANTIRRETROVIRAL BASADA EN INHIBIDORES DE LA INTEGRASA SOBRE EL RESERVORIO VIRAL EN ADULTOS QUE VIVEN CON VIH-1 |
I/II |
YES |
YES |
MIGUEL GORGOLAS HERNANDEZ-MORA |
|
2021-003586-35 |
ESTUDIO FASE I/II OBSERVADOR CIEGO, ALEATORIZADO, INTERNACIONAL Y CONTROLADO CON PLACEBO PARA EVALUAR LA REACTOGENICIDAD, SEGURIDAD, RESPUESTA INMUNE Y EFICACIA DE LA VACUNA FRENTE AL VIRUS HERPES SIMPLEX (VHS) EN SUJETOS SANOS DE 18 A 40 AÑOS O EN PACIENTES DE 18 A 60 AÑOS CON HERPES GENITAL RECURRENTE POR VHS TIPO 2. |
II |
YES |
YES |
MIGUEL GORGOLAS HERNANDEZ-MORA |
|
2023-509588-25-00 |
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF TREATMENT WITH BEPIROVIRSEN IN PARTICIPANTS LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS AND CHRONIC HEPATITIS B |
II |
YES |
YES |
MIGUEL GORGOLAS HERNANDEZ-MORA |
|
2025-521918-26-00 |
ESTUDIO DE FASE 2B, ALEATORIZADO, ABIERTO Y CONTROLADO CON TRATAMIENTO ACTIVO QUE EVALÚA LA SEGURIDAD Y LA EFICACIA DE VH4524184 ORAL COADMINISTRADO CON EMTRICITABINA Y TENOFOVIR ALAFENAMIDA, EN PERSONAS CON VIH-1 VIRÉMICAS QUE NO HAN RECIBIDO TRATAMIENTO PREVIO (ESTUDIO INNOVATE). |
II |
YES |
YES |
MIGUEL GORGOLAS HERNANDEZ-MORA |
|
2024-512505-66-00 |
AN OPERATIONALLY SEAMLESS PHASE 2/3, RANDOMIZED, ACTIVE CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF AN ORAL WEEKLY REGIMEN OF GS-1720 IN COMBINATION WITH GS-4182 VERSUS BIKTARVY IN TREATMENT NAIVE PEOPLE WITH HIV-1 |
II/III |
YES |
YES |
MIGUEL GORGOLAS HERNANDEZ-MORA |
|
2022-502099-22-00 |
A PHASE 3, RANDOMIZED, ACTIVE-CONTROLLED, DOUBLE-BLIND CLINICAL STUDY TO EVALUATE THE ANTIRETROVIRAL ACTIVITY, SAFETY, AND TOLERABILITY OF DORAVIRINE/ISLATRAVIR (DOR/ISL 100 MG/0.25 MG) ONCE-DAILY IN HIV-1 INFECTED TREATMENT-NAÏVE PARTICIPANTS |
III |
YES |
YES |
ALFONSO CABELLO UBEDA |
|
2022-502126-40-00 |
A PHASE 3 OPEN-LABEL CLINICAL STUDY OF DORAVIRINE/ISLATRAVIR (DOR/ISL [100 MG/0.25 MG]) ONCE DAILY FOR THE TREATMENT OF HIV-1 INFECTION IN PARTICIPANTS WHO PREVIOUSLY RECEIVED DOR/ISL (100 MG/0.75 MG) QD IN A PHASE 3 CLINICAL STUDY |
III |
YES |
YES |
ALFONSO CABELLO UBEDA |
|
2023-504993-40-00 |
ESTUDIO DE FASE IIIB, ABIERTO, MULTICÉNTRICO, ALEATORIZADO, DE GRUPOS PARALELOS Y DE NO INFERIORIDAD PARA EVALUAR LA EFICACIA, LA SEGURIDAD Y LA TOLERABILIDAD DE LA COMBINACIÓN DE DOLUTEGRAVIR/LAMIVUDINA ADMINISTRADA POR VÍA ORAL UNA VEZ AL DÍA COMO TRATAMIENTO DE PRIMERA LÍNEA, EN COMPARACIÓN CON LA COMBINACIÓN DE BICTEGRAVIR/EMTRICITABINA/TENOFOVIR ALAFENAMIDA ADMINISTRADA POR VÍA ORAL UNA VEZ AL DÍA, PARA LA INHIBICIÓN Y EL MANTENIMIENTO VIROLÓGICO EN ADULTOS CON VIH SIN TRATAMIENTO ANTIRRETROVIRAL PREVIO |
III |
YES |
YES |
MIGUEL GORGOLAS HERNANDEZ-MORA |
|
2024-515070-28-00 |
A PHASE 3B, OPEN LABEL, RANDOMIZED, STANDARD-OF-CARE CONTROL ARM, MULTICENTER, SUPERIORITY STUDY EVALUATING THE EFFICACY, SAFETY AND TOLERABILITY OF INJECTABLE CAB LA + RPV LA IN VIREMIC PARTICIPANTS LIVING WITH HIV-1 (CROWN) |
III |
YES |
YES |
MIGUEL GORGOLAS HERNANDEZ-MORA |
|
NA |
IMPLEMENTATION OF LONG-ACTING CABOTEGRAVIR + RILPIVIRINE ADMINISTRATION IN DIFFERENT HEALTH SETTINGS (IMADART STUDY) |
IV |
NO |
NO |
ALFONSO CABELLO UBEDA |
|
2021-003847-10 |
EFICACIA Y SEGURIDAD DE 7 VERSUS 14 DÍAS DE TRATAMIENTO ANTIBIÓTICO PARA LA BACTERIEMIA PRODUCIDA POR PSEUDOMONAS AERUGINOSA: UN ENSAYO CLÍNICO MULTICÉNTRICO, ALEATORIZADO (SHORTEN-2) CON UN ANÁLISIS DOOR/RADAR |
IV |
YES |
NO |
ELISABET PETKOVA SAIZ |
|
2023-507293-40-00 |
ESTUDIO EN FASE IV CON DISEÑO DE PRUEBA NEGATIVA PARA EVALUAR LA EFICACIA DE UNA VACUNA CONJUGADA ANTINEUMOCÓCICA 20-VALENTE CONTRA LA NEUMONÍA ADQUIRIDA EN LA COMUNIDAD CAUSADA POR SEROTIPOS VACUNALES CONFIRMADA RADIOLÓGICAMENTE EN ADULTOS |
IV |
YES |
YES |
TERESA ALVAREZ DE ESPEJO MONTIEL |
|
MC1: MULTICENTRE INT2: INTERNATIONAL |
|||||











